An old cancer drug can kill the zombie cells linked to aging
A drug used for decades to treat a rare blood cancer turns out to also clear senescent cells — the so-called zombie cells associated with aging and age-related disease.
Homoharringtonine is a plant-derived alkaloid already used as a chemotherapy agent in chronic myeloid leukemia. It inhibits protein synthesis — the process by which cells manufacture new proteins. Researchers found that senescent cells are particularly vulnerable to this kind of inhibition: they rely more heavily on continuous protein production for their survival than normal cells do, making them disproportionately susceptible. The study places homoharringtonine in the category of senolytics — drugs that selectively destroy senescent cells without severely damaging healthy tissue.
Why senolytic drugs matter
Senescent cells stop dividing but remain alive, secreting substances that damage surrounding tissue and fuel chronic inflammation. In young organisms, they are efficiently removed. With age, they accumulate in organs, joints, blood vessels, and the brain. There is compelling evidence from animal studies that clearing senescent cells extends lifespan, improves health, and delays age-related conditions. The first clinical trials in humans are already underway.
The problem with existing senolytics — the best-known combination being dasatinib and quercetin — is that they are not ideal for long-term use in healthy people due to side effects. The search for better alternatives is therefore active. Homoharringtonine has the advantage of an already extensive safety profile from years of oncological use, though doses in cancer treatment are significantly higher than what would be needed for senolysis.
The promise and the pitfall of repurposed drugs
Repurposing existing drugs for new applications is a popular strategy because the clinical path is shorter and cheaper. But there are downsides. Existing drugs were not designed for their new purpose and often carry a side effect profile that may be unacceptable for a different patient population — in this case, healthy older adults rather than cancer patients. Whether homoharringtonine at the low doses needed for senolysis is safe enough for broad use must be determined in clinical research. For now, the findings are promising but limited to laboratory studies.